These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2284694)

  • 1. Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2.
    Squadrelli-Saraceno M; Rivoltini L; Cantù G; Ravagnani F; Parmiani G; Molinari R
    Tumori; 1990 Dec; 76(6):566-71. PubMed ID: 2284694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
    Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
    Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients.
    Cascinelli N; Belli F; Marchini S; Marolda R; Prada A; Sciorelli G; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G
    Tumori; 1989 Jun; 75(3):233-44. PubMed ID: 2788945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined immunotherapy using interferon-alpha, interleukin-2 and lymphokine-activated killer cells--improvement of quality of life in patients with advanced renal cell carcinoma].
    Watanabe J; Hattori T; Satoh M; Akimoto M
    Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1156-63. PubMed ID: 7609359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interleukin-2 and LAK cells in the local immunotherapy of tumors of the head and neck: an experimental model].
    Sacchi M; Johnson JT; Whiteside TL; Cortesina G
    Acta Otorhinolaryngol Ital; 1989; 9(4):391-8. PubMed ID: 2618654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
    Merchant RE; Grant AJ; Merchant LH; Young HF
    Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study.
    Ferlazzo G; Scisca C; Iemmo R; Cavaliere R; Quartarone G; Adamo V; Frazzetto G; Costa G; Melioli G
    J Immunother; 1997 Mar; 20(2):158-63. PubMed ID: 9087388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.
    Merchant RE; Merchant LH; Cook SH; McVicar DW; Young HF
    Neurosurgery; 1988 Dec; 23(6):725-32. PubMed ID: 2851116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
    Tjota A; Zhang YQ; Piedmonte MR; Lee CL
    J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of local administration of RIL-2 in head and neck cancer].
    Saito T; Kakiuti H; Kuki K; Yokota M; Jinnin T; Kimura T; Fujiwara K; Yoda J; Kunimoto M; Arai H
    Nihon Jibiinkoka Gakkai Kaiho; 1989 Aug; 92(8):1265-70. PubMed ID: 2585201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.